1,441 results on '"Gossec, L"'
Search Results
2. LBA0004 REMOTE MONITORING AND PATIENT-INITIATED CARE COMPARED TO REGULAR FACE-TO-FACE OUTPATIENT VISITS IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM A RANDOMIZED NON-INFERIORITY TRIAL
3. POS0492 GENDER-SPECIFIC PERFORMANCE OF DISEASE ACTIVITY ASSESSMENT TOOLS IN AXIAL SPONDYLOARTHRITIS: ANCILLARY ANALYSIS OF THE PREDICT-SPA STUDY
4. POS0506 THE LONGITUDINAL ASSOCIATION BETWEEN DISEASE ACTIVITY, FUNCTION AND HEALTH-RELATED QUALITY OF LIFE IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE DESIR COHORT
5. POS0889 PATIENT RESEARCH PARTNER INVOLVEMENT IN RHEUMATOLOGY RESEARCH: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2023 UPDATED EULAR RECOMMENDATIONS FOR THE INVOLVEMENT OF PATIENT RESEARCH PARTNERS
6. AB1493 PATIENT SATISFACTION AND EXPERIENCE AFTER A SWITCH TO AN ADALIMUMAB BIOSIMILAR WITH HIGH CONCENTRATION AND CITRATE-FREE: RESULTS FROM A MULTICENTRIC PROSPECTIVE REAL-LIFE STUDY
7. POS0517 GREATER USE OF ASSISTED REPRODUCTIVE TECHNIQUES BUT COMPARABLE OBSTETRIC MORBIDITY IN A POPULATION OF WOMEN WITH SPONDYLOARTHRITIS: A MATCHED COMPARATIVE ANALYSIS OF THE GR2 PROSPECTIVE COHORT AND THE FRENCH NATIONAL PERINATAL SURVEYS
8. AB1511 PERCEIVED NEED FOR TREATMENT IS ASSOCIATED WITH PATIENT SATISFACTION AFTER A SWITCH TO A BIOSIMILAR; HEALTH LITERACY IS OFTEN LIMITED: A PROSPECTIVE MULTICENTRE OBSERVATIONAL STUDY OF 232 PATIENTS
9. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update
10. Impact of Risk Factors on COVID-19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID-19 Global Rheumatology Alliance Registry
11. P884 Patient satisfaction and experience after a switch to an adalimumab biosimilar with high concentration and citrate-free: results from a multicentric prospective real-life study
12. Quelle est la meilleure stratégie pour sevrer un patient en corticoïdes en cas de polyarthrite rhumatoïde en bas niveau d’activité : remplacer par de l’hydrocortisone ou diminuer progressivement la prednisone ? Résultats de l’essai randomisé STAR
13. L’aprémilast améliore l’état des patients atteints du rhumatisme psoriasique de forme oligoarticulaire : analyse principale de l’essai thérapeutique contrôlé vs placebo FOREMOST
14. Surrisque de prématurité chez les nouveau-nés de femmes atteintes de polyarthrite rhumatoïde : analyse comparative appariée de la cohorte prospective GR2-RIC et des enquêtes nationales périnatales françaises
15. L’arthrose digitale érosive est responsable de plus de douleur et d’incapacité fonctionnelle que la polyarthrite rhumatoïde traitée : une étude comparative entre les cohortes DIGICOD et ESPOIR
16. Définir l’altération de la fonction et de la santé globale dans la spondyloarthrite axiale en utilisant l’EQ-5D-3L quand le ASAS-HI n’est pas disponible, est possible. Une analyse de 2651 patients de l’étude PERSPA
17. L’activité de la maladie et le syndrome douloureux chronique sont les éléments clés de la santé globale dans la spondyloarthrite axiale : une analyse de 4 bases de données et 6064 patients
18. Un recours supérieur à la PMA mais une morbidité obstétricale comparable dans une population de femmes atteintes de spondylarthrite: analyse comparative appariée de la cohorte prospective GR2-RIC et des Enquête Nationales Périnatales françaises
19. Rechute de la maladie au cours de la grossesse chez les femmes ayant une polyarthrite rhumatoïde ou une spondyloarthrite : les données de la cohorte française GR2
20. Performance des outils d’évaluation de l’activité de la maladie selon le genre dans la spondyloarthrite axiale : analyse ancillaire de l’étude PREDICT-SpA
21. Implication des patients partenaires de recherche dans la recherche en rhumatologie : où en sommes-nous ? Une revue exploratoire des études récentes
22. Evaluation globale standardisée systématique : quelles pratiques en France ?
23. Problématiques du changement de diagnostic initial et des perdus de vue dans les cohortes de démarrage (inception cohort) : données de la cohorte de spondyloarthrite axiale récente DESIR
24. Maintien de l’efficacité du bimékizumab pendant 52 semaines chez les patients atteints de rhumatisme psoriasique, naïfs de biologique et répondeurs à la semaine 16 : résultats de BE OPTIMAL, étude de phase III avec un bras de référence actif
25. Impact du bimékizumab sur les domaines évalués par le GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) chez les patients atteints de rhumatisme psoriasique (RhPso) : résultats à 52 semaines issus de 4 études de phase III
26. Résultats cliniques à dix ans des patients atteints de spondyloarthrite axiale d’apparition récente : résultats de la cohorte de démarrage DESIR
27. Améliorations cliniquement significatives des critères-patient sous guselkumab chez les patients atteints de rhumatisme psoriasique actif en réponse inadéquate aux anti-TNF : résultats à un an d’une étude de phase 3b, randomisée, contrôlée (COSMOS)
28. Proposition d’un compte rendu standardisé pour une évaluation globale de la spondyloarthrite axiale par une approche basée sur les preuves et un consensus d’experts en rhumatologie (rencontres d’experts en rhumatologie)
29. Effet du post-partum sur les patientes atteintes de rhumatismes inflammatoires chroniques
30. Towards standardized patient reported physical function outcome reporting : linking ten commonly used questionnaires to a common metric
31. Factors associated with the orthopaedic surgeon's decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1905 patients
32. Towards standardized patient reported physical function outcome reporting: linking ten commonly used questionnaires to a common metric
33. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
34. Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebo controlled, active reference BE OPTIMAL study
35. Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT Working Group
36. Risk of severe COVID-19 associated with immune-modifying drugs: Data from PsoProtect and Global Rheumatology Alliance registries.
37. Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
38. Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry
39. POS1533 BIMEKIZUMAB TREATMENT RESULTED IN CLINICALLY MEANINGFUL IMPROVEMENTS IN THE PSORIATIC ARTHRITIS IMPACT OF DISEASE-12 (PSAID-12) SCORES USING POOLED RESULTS FROM TWO PHASE 3 TRIALS IN PATIENTS WITH PSORIATIC ARTHRITIS
40. AB1082 EARLY CLINICAL RESPONSE AS A PREDICTOR OF LONG-TERM HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS IN PATIENTS WITH PSORIATIC ARTHRITIS AND TNFI-IR RECEIVING GUSELKUMAB (COSMOS)
41. AB1687 DOES DISEASE ACTIVITY EXPLAIN HEALTH-RELATED QUALITY OF LIFE IN AXIAL SPONDYLARTHRITIS? A SYSTEMATIC LITERATURE REVIEW
42. OP0062 EULAR POINTS TO CONSIDER FOR THE DEFINITION OF CLINICAL AND IMAGING FEATURES SUSPICIOUS FOR PROGRESSION TO PSORIATIC ARTHRITIS
43. OP0092-HPR THE EFFECTIVENESS OF DIGITAL APPLICATIONS PROVIDING PERSONALIZED EXERCISE VIDEOS IN INDIVIDUALS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES: A SYSTEMATIC REVIEW WITH META-ANALYSIS
44. POS1543 EFFICACY OF RISANKIZUMAB IN THE TREATMENT OF PsA PATIENTS WITH LIMITED AND EXTENSIVE JOINT INVOLVEMENT
45. POS0231 SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR
46. POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMAL
47. POS0590-HPR IDENTIFICATION OF RESPONDER AND DISEASE ACTIVITY THRESHOLDS FOR THE PSORIATIC ARTHRITIS IMPACT OF DISEASE-12 (PSAID-12) QUESTIONNAIRE USING POOLED DATA FROM TWO PHASE 3 TRIALS OF BIMEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS
48. OP0189 REMISSION CRITERIA GUIDING IMMUNOSUPPRESSIVE THERAPY IN RA: WHICH IS BEST FITTED FOR THIS PURPOSE?
49. POS1542 THE PSORIATIC ARTHRITIS IMPACT OF DISEASE (PSAID-12) QUESTIONNAIRE IS VALID IN ARABIC AND STRONGLY LINKED TO DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN ARAB-SPEAKING COUNTRIES: AN ARLAR INITIATIVE
50. POS0103 PAIN AND FUNCTIONAL IMPAIRMENT ARE MORE PROMINENT IN EROSIVE HAND OSTEOARTHRITIS THAN IN TREATED RHEUMATOID ARTHRITIS: A COMPARATIVE STUDY BETWEEN DIGICOD AND ESPOIR COHORTS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.